XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS (Tables)
 9 Months Ended
Sep. 30, 2021
Acquisitions, Divestitures and Other Arrangements [Abstract]  
Disposal Groups, Including Discontinued Operations [Table Text Block]
The following table summarizes the financial impact of divestitures including royalties, which are included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures were not material in all periods presented (excluding divestiture gains or losses).
Three Months Ended September 30,
Net Proceeds(a)
Divestiture (Gains)/LossesRoyalty Income
Dollars in Millions202120202021202020212020
Diabetes Business$153 $129 $— $— $(159)$(148)
Erbitux* Business
4 3 — — — — 
Manufacturing Operations27 — — — — — 
Mature Brands and Other4 41 2 1 (1)(44)
Total$188 $173 $2 $1 $(160)$(192)
Nine Months Ended September 30,
Net Proceeds(a)
Divestiture (Gains)/LossesRoyalty Income
Dollars in Millions202120202021202020212020
Diabetes Business$449 $409 $— $— $(445)$(404)
Erbitux* Business
10 10 — — — — 
Manufacturing Operations50 10 — (1)— — 
Plavix* and Avapro*/Avalide*
5 7 — (12)— — 
Mature Brands and Other56 73 (9)7 (2)(76)
Total$570 $509 $(9)$(6)$(447)$(480)
(a)    Includes royalties received subsequent to the related sale of the asset or business.
Licensing and Other Arrangements [Table Text Block]
The following table summarizes the financial impact of Keytruda* royalties, Tecentriq* royalties, up-front licensing fees and milestones for products that have not obtained commercial approval, which are included in Other (income)/expense, net.
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in Millions2021202020212020
Keytruda* royalties
$(215)$(176)$(611)$(492)
Tecentriq* royalties
(22)— (67)— 
Up-front licensing fees— — — (30)
Contingent milestone income(10)(16)(12)(62)
Amortization of deferred income3 (14)(27)(44)
Other royalties(21)(5)(33)(16)
Total$(265)$(211)$(750)$(644)